Skip to content
HowShorted

LIGAND PHARMACEUTICALS INC short interest in 2021

In 2021, LIGAND PHARMACEUTICALS INC's disclosed short interest ran from 62.20% of shares outstanding on 15 Jan 2021 to 9.66% on 31 Dec 2021, a change of -52.54 percentage points. The year's high was 62.20% on 15 Jan 2021 and its low 9.04% on 31 Mar 2021, averaging 13.69% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 35.08 days on 15 Jan 2021. Full history: LIGAND PHARMACEUTICALS INC.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for LIGAND PHARMACEUTICALS INC in 2021

2021 in figures

Start of year
62.20% (15 Jan 2021)
End of year
9.66% (31 Dec 2021)
Change
-52.54 pp
High
62.20% (15 Jan 2021)
Low
9.04% (31 Mar 2021)
Average
13.69%
Highest days to cover
35.08 (15 Jan 2021)
SEC filings marked
8

Every report in 2021

LIGAND PHARMACEUTICALS INC short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 202162.20%35.08
29 Jan 202137.10%3.90
12 Feb 202117.05%3.28results (8-K)
26 Feb 202113.32%5.0510-K filed
15 Mar 202111.22%6.59
31 Mar 20219.04%6.97
15 Apr 20219.45%13.55
30 Apr 20219.72%17.77
14 May 20219.58%10.28results (8-K), 10-Q filed
28 May 20219.54%11.75
15 Jun 202110.33%10.84
30 Jun 202110.52%8.00
15 Jul 202110.56%16.09
30 Jul 20219.89%12.78results (8-K)
13 Aug 20219.70%13.7510-Q filed
31 Aug 20219.64%6.13
15 Sep 202110.65%3.24
30 Sep 202110.40%12.58
15 Oct 20219.98%17.63
29 Oct 20219.95%20.03
15 Nov 20219.50%10.0510-Q filed, results (8-K)
30 Nov 20219.60%13.27
15 Dec 202110.07%16.82
31 Dec 20219.66%10.31

See also: LIGAND PHARMACEUTICALS INC's full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.